PCI complications: Hemodynamic Support for Complex PCI
Hemodynamic Support for Complex PC
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Anahita Deylamsalehi, M.D.[2]
Overview
Pathophysiology
Rapid hemodynamic deterioration and death during PCI can occur due to hypotension, decompensated heart failure, shock, or arrhythmias.[1][2][3]
Prevention
Hemodynamic Support Devices
- Intra-aortic balloon pump
- Can provide minimal hemodynamic support for PCI but is capable of improving coronary and cerebral blood flow.[1]
- But its usage is limited in patients with severe peripheral artery or aortic disease.[1]
- One of the advantages of this device is the small catheter size which reduces the risk of vascular access site complications. Moreover, ease of use is another advantage of intra-aortic balloon pump.
2021 ACA Revascularization Guideline
Class 2b Recommendation, Level of Evidence: B-R [1] |
Using an appropriate hemodynamic support device in the elective settings and among selected patients is reasonable to prevent hemodynamic compromise during PCI. |
References
- ↑ 1.0 1.1 1.2 1.3 Writing Committee Members. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM; et al. (2022). "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol. 79 (2): e21–e129. doi:10.1016/j.jacc.2021.09.006. PMID 34895950 Check
|pmid=
value (help). - ↑ Perera D, Stables R, Thomas M, Booth J, Pitt M, Blackman D; et al. (2010). "Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial". JAMA. 304 (8): 867–74. doi:10.1001/jama.2010.1190. PMID 20736470.
- ↑ O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J; et al. (2012). "A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study". Circulation. 126 (14): 1717–27. doi:10.1161/CIRCULATIONAHA.112.098194. PMID 22935569.